U.S. stock market update: Zhengye Biotechnology down 15.88%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Eli Lilly fell 0.53%, with increased trading volume. Based on recent important news: On September 24, Eli Lilly announced a $6.5 billion investment to build a factory in Houston, Texas, to enhance the production capacity of small molecule drugs, particularly for orforglipron. This move aims to address the surge in demand for weight loss drugs in the U.S. market, driving stock price volatility. Data source: company announcement. On September 23, South Korea's Celltrion acquired Eli Lilly's manufacturing facility in New Jersey for $330 million, planning to expand to avoid U.S. tariff risks. This transaction has sparked market interest in Eli Lilly's future capacity layout. Data source: company statement. On September 22, Lilly Endowment Inc reported selling Eli Lilly common stock, raising market concerns about changes in the company's shareholder structure. Data source: EDGAR system. The GLP-1 drug market is rapidly growing, with increasing policy risks. Pfizer fell 0.02%, with increased trading volume. Based on recent important news: On September 22, Pfizer announced the acquisition of weight loss drug company Metsera for $7.3 billion, aiming to strengthen its position in the obesity drug market. This move led to a 60% surge in Metsera's stock price, while Pfizer's stock rose about 2% in early trading. On September 22, Jefferies raised Pfizer's target price from $33 to $34, reflecting market confidence in Pfizer's future development. On September 22, analysts pointed out that Pfizer's acquisition deal may face integration risks, but it could also narrow the gap with competitors. The obesity drug market is highly competitive, and risks need to be monitored. Merck rose 0.61% based on recent key news: On September 23, Merck announced it would hold a third-quarter earnings call on November 4, and market expectations for its financial performance may drive stock prices up. Data source: Public Technologies. On September 22, market analysts rated Merck as "moderate buy," but it was not included in the top recommended stocks list, which may affect investor confidence. Data source: MarketBeat. The Federal Reserve's interest rate cuts impact market sentiment. Stocks with High Market Capitalization in the Industry Johnson & Johnson fell 0.10%, with a market capitalization of $424.9 billion. Based on recent important news: On September 23, Johnson & Johnson announced it would withdraw its LINX gastroesophageal reflux management system from non-U.S. markets. This move is for commercial reasons, not safety or efficacy issues, which may affect market expectations for its international business. On September 23, Guggenheim raised Johnson & Johnson's target stock price from $167 to $206, reflecting market confidence in its future growth On September 22, Johnson's PD-1 monoclonal antibody did not achieve statistically significant results in the Phase II study for rheumatoid arthritis, which may impact market expectations for its research and development pipeline. Innovative technologies in the pharmaceutical industry continue to advance